What Researchers Did
Researchers conducted a phase 2B randomized trial to evaluate different dosing strategies of hyperbaric oxygen therapy (HBOT) for hospitalized ulcerative colitis patients experiencing moderate to severe flares.
What They Found
Among 20 patients, 55% (11/20) showed a response by Day 3, with significant reductions in stool frequency, rectal bleeding, and CRP (P < 0.01). A 5-day HBOT course led to a more significant reduction in disease activity compared to 3 days (P = 0.03), and only 15% of patients required infliximab or colectomy, much lower than the predicted 80%. Notably, Day 3 HBOT responders had a 0% re-hospitalization or colectomy rate by 3 months, compared to 66% for non-responders.
What This Means for Canadian Patients
For Canadian patients hospitalized with moderate to severe ulcerative colitis flares, this study suggests that hyperbaric oxygen therapy, particularly a 5-day course, could enhance the effectiveness of intravenous steroids. This may lead to a reduced need for more aggressive treatments like infliximab or colectomy, and potentially lower rates of re-hospitalization.
Canadian Relevance
No direct Canadian connection identified. Ulcerative colitis is not a Health Canada-recognized indication for hyperbaric oxygen therapy.
Study Limitations
A key limitation of this study is its small sample size (20 patients) and its phase 2B nature, meaning larger phase 3 trials are needed to confirm efficacy.